

CLINICAL POLICY AND PROCEDURE MANUAL

Policy Number: PA.251.CC Last Review Date: 04/18/2023 Effective Date: 07/15/2023

PA.251.CC Fertility Preservation for latrogenic Infertility

Summary

Public Act 100-1102 requires the Department of Healthcare and Family Services (HFS) to cover medically necessary expenses for standard fertility preservation services when related to interesting infertility, which may be directly or indirectly caused by a necessary medical treatment.

"latrogenic infertility" means an impairment of fertility by surgery, radiation, chemotherapy, or other medical treatment affecting reproductive organs or processes.

"May directly or indirectly cause" means the likely possibility that treatment will cause a side effect of infertility, based upon current evidence-based standards of care established by the American Society for Reproductive Medicine, the American Society of Clinical Oncology, or other national medical associations that follow current evidence-based standards of care.

Policy

CountyCare Health Plan will cover medically necessary fertility preservation services for participants ages 14 through 45 due to iatrogenic infertility. Services will be limited to office visits, pelvic ultrasounds, sperm and oocyte cryopreservation and storage, medications/injectables and laboratory testing.

Covered procedures will require prior authorization.

Clinical Criteria

Medical notes documenting the following, when applicable:

- Initial history and physical
- All clinical notes including rationale for proposed treatment plan
- All ovarian stimulation sheets
- All operative reports
- Laboratory report FSH, AMH, estradiol, and any other pertinent information
- Ultrasound report antral follicle count and any other pertinent information



Policy Number: PA.251.CC Last Review Date: 04/18/2023 Effective Date: 07/05/2023

- Hysterosalpingography (HSG) report
- Semen analysis
- Genetic testing
- Testicular biopsies

Limitations & Exclusions

Medically necessary fertility preservation services are limited to:

- Participants ages 14 through 45
- Office visits
- Pelvic ultrasounds
- Sperm and oocyte cryopreservation and storage
- Medications/injectables
- Laboratory testing
- Other limitations as outlined per Department of Healthcare and Family Services (HFS)

Codes

- These codes are not intended to be all inclusive and are included for informational purposes only.
- Inclusion or exclusion of any codes does not guarantee coverage.
- Providers should reference the Department of Healthcare and Family Services (HFS) for professional coding guidance prior to the submission of claims for reimbursement of covered services.

CPT Codes / HCPCS Codes / ICD-10 Codes			
Code	Description		
58970	Follicle Puncture for oocyte retrieval, any method		
89250	Culture of oocyte(s)/embryo(s), less than 4 days		
89251	Culture of oocyte(s)/embryo(s), less than 4 days; with co-culture of oocyte(s)/embryos		
89253	Assisted embryo hatching, micro techniques (any method)		
89254	Oocyte identification from follicular fluid		
89258	Cryopreservation, embryo(s) (freezing services, not storage)		
89259	Cryopreservation; sperm		



Policy Number: PA.251.CC Last Review Date: 04/18/2023 Effective Date: 07/05/2023

89260	Sperm isolation; simple prep (e.g., sperm wash and swim-up) for insemination or diagnosis with semen analysis	
89261	Sperm isolation; complex prep (e.g., Percoll gradient, albumin gradient) for insemination or diagnosis with semen analysis	
89264	Sperm identification from testis tissue, fresh or cryopreserved	
89268	Insemination of oocytes	
89272	Extended culture of oocytes/embryo(s), 4-7 days	
89280	Assisted oocyte fertilization, microtechnique; less than or equal to 10 oocytes	
89281	Assisted oocyte fertilization, microtechnique; greater than 10 oocytes	
89320	Semen analysis; volume, count motility and differential	
89337	Cryopreservation, mature oocyte(s)	
89342	Storage, (per year); embryo(s)	
89343	Storage, (per year); sperm/semen	
89346	Storage, (per year); oocyte(s)	
99000	Handling and/or conveyance of specimen for transfer from office to a laboratory	
99001	Handling and/or conveyance of specimen for transfer from the patient in other than an office to a laboratory (distance may be indicated)	
99070	Supplies and materials (except spectacles), provided by the physician or other qualified health care professional over and above those usually included with the office visit or other services rendered (list drugs, trays, supplies, or materials provided)	
99078	Physician or other qualified health care professional qualified by education, training, licensure/regulation (when applicable) educational services in a group setting (e.g., prenatal, obesity, or diabetic instructions)	
S0122	Injection, menotropins, 75 IU	
S0126	Injection, follitropin alfa, 75 IU	
S0128	Injection, follitropin beta, 75 IU	
S0132	Injection, ganirelix acetate 250 mcg	
S4011	In vitro fertilization; including but not limited to identification and incubation of mature oocytes, fertilization with sperm, incubation of embryo(s), and subsequent visualization for determination of development	
S4022	Assisted oocyte fertilization, case rate	
S4030	Sperm procurement and cryopreservation services; initial visit	
	I I	



Policy Number: PA.251.CC Last Review Date: 04/18/2023 Effective Date: 07/05/2023

S4031	Sperm procurement and cryopreservation services; subsequent visit
ICD-10 Code	Description
Z31.84	Encounter for fertility preservation procedure

• <u>Z31.62</u> Encounter for fertility preservation counseling

References

- Coverage for fertility preservation services. (Source: P.A. 100-1102, eff. 1-1-19; 101-81, eff. 7-12-19.) 215 ILCS 5/356z.32 (ilga.gov). https://www.ilga.gov/legislation/ilcs/documents/021500050K356z.32.htm
- Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer. American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500-2510. doi:10.1200/JCO.2013.49.2678. https://pubmed.ncbi.nlm.nih.gov/23715580/
- Coccia PF, Pappo AS, Beaupin L, et al. Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16(1):66-97. doi:10.6004/jnccn.2018.0001. https://pubmed.ncbi.nlm.nih.gov/29295883/
- ACOG: Committee Opinion No. 584: oocyte cryopreservation. Obstet Gynecol. 2014 Jan;123(1):221-222. doi: 10.1097/01.AOG.0000441355.66434.6d. PMID: 24463693. Published January 2014 (reaffirmed 2020). https://pubmed.ncbi.nlm.nih.gov/24463693/
- Practice Committee of American Society for Reproductive Medicine. Ovarian tissue cryopreservation: a committee opinion. Fertil Steril. 2014;101(5):1237-1243. doi:10.1016/j.fertnstert.2014.02.052. Epub 2014 Mar 28. PMID: 24684955. https://pubmed.ncbi.nlm.nih.gov/24684955/
- Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril. 2013;99(1):37-43. doi:10.1016/j.fertnstert.2012.09.028. Epub 2012 Oct 22. PMID: 23083924. https://pubmed.ncbi.nlm.nih.gov/23083924/
- Shah JS, Guerra R, Bodurka DC, Sun CC, Chisholm GB, Woodard TL. Factors influencing fertility-sparing treatment for gynecologic malignancies: A survey of Society of Gynecologic Oncology members. Gynecol Oncol. 2017;147(3):497-502. doi:10.1016/j.ygyno.2017.09.019. Epub 2017 Sep 21. PMID: 28941656. https://pubmed.ncbi.nlm.nih.gov/28941656/
- 8. Ovarian tissue cryopreservation for preservation of fertility in patients undergoing gonadotoxic cancer treatment. Hayes. www.hayesinc.com. Published October 1, 2019 (Annual review January 18, 2021). Annual Review: December 8, 2022.



Policy Number: PA.251.CC Last Review Date: 04/18/2023 Effective Date: 07/05/2023

- https://www.hayesinc.com/publications/evidence-analysis/health-technology-assessment/ovarian-tissue-cryopreservation-for-preservation-of-fertility-in-patients-undergoing-gonadotoxic-cancer-treatment/htb-ovarian3754/
- Pacheco F, Oktay K. Current Success, and Efficiency of Autologous Ovarian Transplantation: A Meta-Analysis. Reprod Sci. 2017;24(8):1111-1120. doi:10.1177/1933719117702251. Epub 2017 Jul 13. PMID: 28701069. https://pubmed.ncbi.nlm.nih.gov/28701069/
- 10. Oktay K, Harvey BE, Partridge AH, et al. Fertility Preservation in Patients with Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018;36(19):1994-2001. doi:10.1200/JCO.2018.78.1914. Epub 2018 Apr 5. PMID: 29620997. https://pubmed.ncbi.nlm.nih.gov/29620997/
- 11. The American College of Obstetricians and Gynecologists. Gynecologic Issues in Children and Adolescent Cancer Patients and Survivors No.747. Published August 2018 (reaffirmed 2021). https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2018/08/gynecologic-issues-in-children-and-adolescent-cancer-patients-and-survivors
- 12. Sonmezer M, Oktay K. Overview of fertility and reproductive hormone preservation prior to gonadotoxic therapy or surgery. UptoDate. www.uptodate.com. Published December 6, 2020. Last Upated: July 8,2022. https://www.uptodate.com/contents/fertility-and-reproductive-hormone-preservation-overview-of-care-prior-to-gonadotoxic-therapy-or-surgery
- 13. American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. December 2019.

https://www.asrm.org/globalassets/asrm/asrm-content/news-andpublications/practice-guidelines/for-nonmembers/fertility_preservation_in_patients_undergoing_gonadotoxic_therapy_or_ gonadectomy.pdf

Revision History

Revision	Date
Policy Created	02/2023

Disclaimer

CountyCare medical payment and prior authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. The policies constitute only the reimbursement and coverage guidelines of CountyCare



Policy Number: PA.251.CC Last Review Date: 04/18/2023 Effective Date: 07/05/2023

and its affiliated managed care entities. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies.

CountyCare reserves the right to review and update the medical payment and prior authorization guidelines in its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.

These policies are the proprietary information of Evolent Health. Any sale, copying, or dissemination of said policies is prohibited.

